Science
Mechanism of Action
This extract combats oxidative stress by decreasing intracellular malondialdehyde, increasing superoxide dismutase activity, and reducing reactive oxygen species accumulation, effectively protecting human keratinocytes. Its anti-inflammatory action is mediated through the upregulation of the Nrf2/HO-1 pathway and the inhibition of NF-κB activation, subsequently reducing pro-inflammatory mediators such as nitric oxide, prostaglandin E2, iNOS, COX-2, TNF-α, and IL-1β. Furthermore, bioactive compounds within the extract suggest potential for inhibiting tyrosinase and elastase, contributing to anti-aging effects like skin brightening and wrinkle prevention. Traditionally, it exhibits astringent qualities.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 In a mouse model, Erigeron annuus extract (500-1000 mg/kg, oral) ameliorated DNCB-induced atopic dermatitis by upregulating the Nrf2/HO-1 pathway, showing non-toxicity.
- 02 In vitro pre-treatment with Erigeron annuus extract protected H2O2-stimulated human keratinocytes against oxidative stress, evidenced by reduced malondialdehyde, increased superoxide dismutase, and decreased reactive oxygen species.
- 03 Erigeron annuus extract demonstrated anti-inflammatory effects in a protein denaturation assay.
- 04 Erigeron annuus root extract significantly inhibited iNOS and COX-2 protein expressions in LPS-stimulated Raw264.7 cells.
- 05 Erigeron annuus root extract inhibited the production of pro-inflammatory cytokines TNF-α and IL-1β in LPS-stimulated Raw264.7 cells.
Transparency
Dusting Analysis
Insufficient data to determine dusting characteristics for topical application.
The Formula
Formulation
Stability
While one in vitro study utilized an extract solution at pH 7.6 for anti-inflammatory testing, this condition is not definitively stated as optimal for extract stability.
Conflicts
- Individuals with known allergies to plants within the Asteraceae family (e.g., ragweed, chamomile, calendula).
- General caution advised with blood thinners due to potential systemic interactions, although primarily relevant for internal use.
Safety
Safety Profile
No specific CIR or SCCS safety assessments have been identified. The FDA has not evaluated traditional use claims. There is a potential risk for contact dermatitis or allergic reactions, particularly for individuals sensitive to Asteraceae family plants. Caution is generally advised for use during pregnancy or breastfeeding, though this is primarily in the context of internal consumption.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Erigeron Annuus Leaf Extract is a valuable botanical ingredient, demonstrating strong antioxidant and anti-inflammatory properties crucial for skin health and repair, with potential anti-aging benefits, though further human topical studies would enhance its profile.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources